These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 6211659)

  • 41. [Echocardiographic and polycardiographic findings in multiple-transfused patients with thalassemia major].
    Orlandi G; Sticca M; Zanini R; Caminiti A
    Pediatr Med Chir; 1982; 4(1-2):61-4. PubMed ID: 7111041
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Normal serum ferritin levels following prolonged desferrioxamine therapy: Melbourne experience.
    Matthews RN
    Birth Defects Orig Artic Ser; 1988; 23(5B):117-22. PubMed ID: 3390533
    [No Abstract]   [Full Text] [Related]  

  • 43. [Thoughts apropos of 2 cases of major thalassemia and its treatment by desferrioxamine B].
    Manassero J; Eskenazi R; Maissa S
    Pediatrie; 1966 Sep; 21(6):721-2. PubMed ID: 5954605
    [No Abstract]   [Full Text] [Related]  

  • 44. The effect of subcutaneous deferoxamine on the cardiac profile of thalassemia major: a five-year study.
    Giardina PJ; Ehlers KH; Engle MA; Grady RW; Hilgartner MW
    Ann N Y Acad Sci; 1985; 445():282-92. PubMed ID: 3860132
    [No Abstract]   [Full Text] [Related]  

  • 45. Subcutaneous diethylene triamine pentaacetic acid: comparison with desferrioxamine in thalassemic patients with iron overload.
    Pippard MJ; Jackson MJ; Modell CB
    Birth Defects Orig Artic Ser; 1988; 23(5B):105-9. PubMed ID: 3390531
    [No Abstract]   [Full Text] [Related]  

  • 46. Ocular changes in patients undergoing long-term desferrioxamine treatment.
    Arden GB; Wonke B; Kennedy C; Huehns ER
    Br J Ophthalmol; 1984 Dec; 68(12):873-7. PubMed ID: 6509007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Desferrioxamine and ascorbic acid supplement in E-B thalassaemia.
    Dutta AK; Ray R; Chandra S; Bhattacharya DK
    J Assoc Physicians India; 1988 Jul; 36(7):463-4. PubMed ID: 3204100
    [No Abstract]   [Full Text] [Related]  

  • 48. Acute renal insufficiency occurring during intravenous desferrioxamine therapy.
    Batey R; Scott J; Jain S; Sherlock S
    Scand J Haematol; 1979 Mar; 22(3):277-9. PubMed ID: 451459
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine.
    Marsh MN; Holbrook IB; Clark C; Shaffer JL
    Postgrad Med J; 1981 Sep; 57(671):582-4. PubMed ID: 7329898
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanism of desferrioxamine-induced iron excretion in thalassaemia.
    Hershko C; Rachmilewitz EA
    Br J Haematol; 1979 May; 42(1):125-32. PubMed ID: 465354
    [No Abstract]   [Full Text] [Related]  

  • 51. Ocular involvement correlated with age in patients affected by major and intermedia beta-thalassemia treated or not with desferrioxamine.
    Rinaldi M; Della Corte M; Ruocco V; D'Onofrio C; Zanotta G; Romano A
    Metab Pediatr Syst Ophthalmol (1985); 1993; 16(1-2):23-5. PubMed ID: 8259071
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Echocardiographic a profile of 92 subjects with thalassemia major].
    Comi LI; De Angelis P; Mastrobuoni A; De Rosa L; Stefanelli S; Lupi L; Petretta V; Giordano E
    Boll Soc Ital Cardiol; 1979; 24(9):1001-18. PubMed ID: 553645
    [No Abstract]   [Full Text] [Related]  

  • 53. [Desferrioxamine B treatment of 4 splenectomized cases of Cooley's anemia].
    Rossi R; Frangini V; Pratesi C
    Riv Clin Pediatr; 1968; 81(5):1002-9. PubMed ID: 5740180
    [No Abstract]   [Full Text] [Related]  

  • 54. Maintenance treatment with desferrioxamine via subcutaneous injections in a patient with HbE thalassaemia.
    van Deursen CT; Goey SH; Fickers MM
    Neth J Med; 1988 Oct; 33(3-4):178-81. PubMed ID: 3226450
    [No Abstract]   [Full Text] [Related]  

  • 55. Long-term desferrioxamine therapy in thalassemia.
    Modell CB; Beck J
    Ann N Y Acad Sci; 1974; 232(0):201-10. PubMed ID: 4528634
    [No Abstract]   [Full Text] [Related]  

  • 56. Deferoxamine-induced bone dysplasia in patients with thalassemia major.
    Brill PW; Winchester P; Giardina PJ; Cunningham-Rundles S
    AJR Am J Roentgenol; 1991 Mar; 156(3):561-5. PubMed ID: 1899759
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Growth plate injury of the long bones in treated beta-thalassemia.
    Orzincolo C; Scutellari PN; Castaldi G
    Skeletal Radiol; 1992; 21(1):39-44. PubMed ID: 1546335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Survival and desferrioxamine in thalassaemia major.
    Modell B; Letsky EA; Flynn DM; Peto R; Weatherall DJ
    Br Med J (Clin Res Ed); 1982 Apr; 284(6322):1081-4. PubMed ID: 6802413
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Importance of treatment with deferoxamine in children with Cooley's disease].
    Taccone F; Monaco L
    Minerva Pediatr; 1967 Dec; 19(50):2255-9. PubMed ID: 5606770
    [No Abstract]   [Full Text] [Related]  

  • 60. Ocular findings in beta-thalassemia.
    Sorcinelli R; Sitzia A; Figus A; Lai ME
    Metab Pediatr Syst Ophthalmol (1985); 1990; 13(1):23-5. PubMed ID: 2370833
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.